Orsobio Announces Acquisition Of Lxr Inverse Agonist Program For Treatment Of Severe Dyslipidemias From Phenex Pharmaceuticals

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of assets relating to the Liver X Receptor (LXR) inverse agonist program from Phenex Pharmaceuticals, including lead candidate TLC-2716 and associated intellectual property. The company will present preclinical data describing the efficacy of TLC-2716 in dysmetabolic rodents and human liver organoids (HLOs) at AASLD’s The Liver Meeting®, as it continues a Phase 1, first-in-human study for which data are expected in early 2023.